New research led by Duke AI Health Director Michael Pencina, PhD, published recently in the journal Circulation, looked at the value of using a genomic test to predict the future risk of heart disease. Pencina and colleagues found that the genomic test, referred to as the polygenic risk score (PRS), only marginally added to the predictive information obtained through the assessment of traditional risk factors, concluding that the PRS “had minimal clinical utility”.
